Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ ... However, signs of recovery are emerging, according to data shared by the Alliance for Regenerative Medicine at ...

Health Canada has approved Moderna's mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older, ...

Sales of Moderna's new RSV vaccine mRESVIA were $10 million, far short of the $135 million analysts had expected, according to data compiled by LSEG. "We were not able to compete during the heart ...

While Novavax's 2024-2025 updated vaccine targets the JN.1 variant, and not KP.2 like Pfizer and Moderna, Novavax has reported that non-clinical data has demonstrated broad cross-neutralizing ...